GW Pharmaceuticals

GW is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, EPIDIOLEX (cannabidiol) oral solution, is commercialized in the U.S. by its U.S. subsidiary Greenwich Biosciences for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome, or tuberous sclerosis complex (TSC) in patients one year of age and older. This product has received approval in the European Union under the tradename EPIDYOLEX for the adjunctive treatment of seizures associated with LGS or Dravet syndrome in conjunction with clobazam in patients two years and older and is under EMA review for the treatment of TSC. The Company has a deep pipeline of additional cannabinoid product candidates, in particular nabiximols, for which the Company is advancing multiple late-stage clinical programs in order to seek FDA approval in the treatment of spasticity associated with multiple sclerosis and spinal cord injury. The Company has additional cannabinoid product candidates in clinical trials for autism and schizophrenia.

Curaleaf Holdings, Inc.

These stocks were beating the S&P 500 entering July.

Got $5,000? These 2 Market-Beating Pot Stocks Are Still Hot Buys Right Now

This is yet another reminder that all next-big-thing investments need time to mature.

Face the Facts: The CBD Hype Train Has Derailed

Aurora Cannabis

Aphria

Canopy Growth

Cronos Group

HEXO Corp

Since the middle of last year, marijuana stocks have taken a major beating. The best performing of the Canadian cultivation and retail stocks is down by more than a quarter, and the worst is down more than 85%.

Could These 6 Marijuana Stocks Recapture Much of Their Stock Losses?

GrowGeneration Corp

Scotts Miracle-Gro

Momentum for these marijuana stocks from the first half of the year should continue in the second half, too.

3 Marijuana Stock Winners in the First Half of 2020 That Are Still Great Picks

Innovative Industrial Properties

Green Thumb Industries Inc.

Trulieve Cannabis Corp.

Hint: You won't find any Canadian marijuana stocks on this list.

The 5 Best Pot Stocks in the First Half of 2020

Amyris

Cara Therapeutics

Tilray Brands

These marijuana stocks on the Nasdaq are top for value, growth, and performance for July 2020.

Top Marijuana Stocks on the NASDAQ for July 2020

Is GW Pharmaceuticals Stock a Buy?

 - Potential accelerated pathway to NDA submission - - Clinical program of five Phase 3 trials provides multiple options for NDA submission, as early as 2021 - - Webcast featuring a range of guest speakers to be held today from 10:00am-12:00pm EDT -

GW Pharmaceuticals Presents Nabiximols U.S. Development and Commercial Strategy

Here's why this shares of this cannabinoid drug company will keep soaring within the next year.

Where Will GW Pharmaceuticals Be in 1 Year?

Both of these biotechs could have big catalysts on the way.

Better Buy: GW Pharmaceuticals vs. Cara Therapeutics

Mastercard

NVIDIA

DocuSign

We used TipRanks analyst ranking service to pinpoint Wall Street's best-performing analysts.

Top analysts are betting on stocks like Mastercard and Nvidia right now into the second half

Zynerba Pharmaceuticals

The marijuana stocks plunged during the coronavirus sell-off. Should investors be taking a second look?

Is This a Buying Opportunity in the Marijuana Stocks?

GW Pharmaceuticals PLC (NASDAQ: GWPH) took a big step forward for the development of its cannabidiol in the United Kingdom.

GW Pharma Makes Big Regulatory Step for Cannabidiol in UK

GW’s cannabis-based medicine rescheduled following approval by the European Medicines Agency (EMA) and an independent assessment by the Advisory Council on the Misuse of Drugs (ACMD)

GW Pharmaceuticals announces that EPIDYOLEX® (cannabidiol) has been reclassified by the UK Home Office as a Schedule 5 drug

And why the federal legalization of pot in the U.S. is probably a long way off.

2 Ways the Cannabis Industry Is Shooting Itself in the Foot

Amplify Seymour Cannabis ETF

Amplify Online Retail ETF

CNBC's cannabis expert Tim Seymour discusses the outlook for the industry.

Is it Time to Buy Cannabis Stocks & ETFs?

GW Pharma has been performing well recently, but is this cannabis stock a buy?

1 Cannabis Stock Beating the Market This Year

The maker of Epidiolex is showing positive momentum after a tremendous first quarter.

GW Pharmaceuticals Is Picking Up Steam in 2020

Golar LNG

Gossamer Bio Inc

Lexinfintech Hlds

Nextcure

SINA

Millicom International Cellular S.A.

Casinos are just starting to open back up following COVID-19 shutdowns, but it may still be a while before some gamblers are willing to venture back to Vegas or even their local casino.

7 High-Risk Stocks For Market Gamblers

Village Farms International

These are the NASDAQ-listed marijuana stocks with the best value, fastest growth, and most momentum for June.

Top Marijuana Stocks on the NASDAQ for June 2020

GW Pharma: Analysts Aren't Thinking Clearly

Amplify Alternative Harvest ETF

Researchers in Alberta have discovered cannabis may become a surprising addition in the global battle against the coronavirus.

Cannabis May Show Promise in Treating COVID-19. Here's What It Means for the Pot Industry.

Shopify

There are some attractive options for growth investors, even amid the rout in the broader cannabis sector.

3 Safe Cannabis Stocks to Hold During the COVID-19 Pandemic

Nearly everything that could go right went right for the cannabis-focused drugmaker.

How GW Pharmaceuticals Hit a Home Run in Q1

GW Pharmaceuticals PLC (GWPH) CEO Justin Gover on Q1 2020 Results - Earnings Call Transcript

News for GW Pharmaceuticals Stock (GWPH)